These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 14675856)

  • 1. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography.
    Ng LL; Loke I; Davies JE; Khunti K; Stone M; Abrams KR; Chin DT; Squire IB
    Eur J Heart Fail; 2003 Dec; 5(6):775-82. PubMed ID: 14675856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.
    Vasan RS; Benjamin EJ; Larson MG; Leip EP; Wang TJ; Wilson PW; Levy D
    JAMA; 2002 Sep; 288(10):1252-9. PubMed ID: 12215132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides.
    Ng LL; Loke IW; Davies JE; Geeranavar S; Khunti K; Stone MA; Chin DT; Squire IB
    J Am Coll Cardiol; 2005 Apr; 45(7):1043-50. PubMed ID: 15808762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.
    Ng LL; Pathik B; Loke IW; Squire IB; Davies JE
    Am Heart J; 2006 Jul; 152(1):94-101. PubMed ID: 16824837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QRS prolongation on surface ECG and brain natriuretic peptide as indicators of left ventricular systolic dysfunction.
    Krüger S; Filzmaier K; Graf J; Kunz D; Stickel T; Hoffmann R; Hanrath P; Janssens U
    J Intern Med; 2004 Feb; 255(2):206-12. PubMed ID: 14746557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction.
    Davidson NC; Naas AA; Hanson JK; Kennedy NS; Coutie WJ; Struthers AD
    Am J Cardiol; 1996 Apr; 77(10):828-31. PubMed ID: 8623734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate.
    Loke I; Squire IB; Davies JE; Ng LL
    Eur J Heart Fail; 2003 Oct; 5(5):599-606. PubMed ID: 14607197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical detection of left-ventricular systolic dysfunction.
    McDonagh TA; Robb SD; Murdoch DR; Morton JJ; Ford I; Morrison CE; Tunstall-Pedoe H; McMurray JJ; Dargie HJ
    Lancet; 1998 Jan; 351(9095):9-13. PubMed ID: 9433422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.
    Omland T; Aakvaag A; Bonarjee VV; Caidahl K; Lie RT; Nilsen DW; Sundsfjord JA; Dickstein K
    Circulation; 1996 Jun; 93(11):1963-9. PubMed ID: 8640969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy.
    Yamamoto K; Burnett JC; Jougasaki M; Nishimura RA; Bailey KR; Saito Y; Nakao K; Redfield MM
    Hypertension; 1996 Dec; 28(6):988-94. PubMed ID: 8952587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population.
    Nakamura M; Endo H; Nasu M; Arakawa N; Segawa T; Hiramori K
    Heart; 2002 Feb; 87(2):131-5. PubMed ID: 11796549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population.
    Nielsen OW; McDonagh TA; Robb SD; Dargie HJ
    J Am Coll Cardiol; 2003 Jan; 41(1):113-20. PubMed ID: 12570953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study.
    de Lemos JA; McGuire DK; Khera A; Das SR; Murphy SA; Omland T; Drazner MH
    Am Heart J; 2009 Apr; 157(4):746-53.e2. PubMed ID: 19332205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.
    Nousiainen T; Vanninen E; Jantunen E; Puustinen J; Remes J; Rantala A; Vuolteenaho O; Hartikainen J
    J Intern Med; 2002 Mar; 251(3):228-34. PubMed ID: 11886482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natriuretic peptides and the prevalence of congestive heart failure in patients with pacemakers.
    Gwechenberger M; Huelsmann M; Graf S; Berger R; Bonderman D; Stanek B; Rauscha F; Pacher R
    Eur J Clin Invest; 2004 Dec; 34(12):811-7. PubMed ID: 15606723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide].
    Tarantini L; Cioffi G; Di Lenarda A; Valle R; Pulignano G; Del Sindaco D; Frigo G; Soravia G; Tessier R; Catania G
    G Ital Cardiol (Rome); 2008 Dec; 9(12):835-43. PubMed ID: 19119693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women.
    Hedberg P; Lönnberg I; Jonason T; Nilsson G; Pehrsson K; Ringqvist I
    Am Heart J; 2004 Sep; 148(3):524-9. PubMed ID: 15389243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic potential of cardiac natriuretic peptides in dialysis patients.
    Mallamaci F; Zoccali C; Tripepi G; Benedetto FA; Parlongo S; Cataliotti A; Cutrupi S; Giacone G; Bellanuova I; Stancanelli B; Malatino LS;
    Kidney Int; 2001 Apr; 59(4):1559-66. PubMed ID: 11260421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction.
    Falcão LM; Pinto F; Ravara L; van Zwieten PA
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):121-9. PubMed ID: 15526247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BNP in the community - still work to be done..
    Rao A; Hodgson L; Pearce D; Walsh J
    Int J Cardiol; 2008 Feb; 124(2):228-30. PubMed ID: 17363081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.